ADAM17 selectively activates the IL‐6 trans‐signaling/ERK MAPK axis in KRAS‐addicted lung cancer

ADAM17 selectively activates the IL‐6 trans‐signaling/ERK MAPK axis in KRAS‐addicted lung cancer

Abstract Oncogenic KRAS mutations are major drivers of lung adenocarcinoma (LAC), yet the direct therapeutic targeting of KRAS has been problematic. Here, we reveal an obligate requirement by oncogenic KRAS for the ADAM17 protease in LAC. In genetically engineered and xenograft (human cell line and...

Full description

Bibliographic Details
Main Authors: Mohamed I Saad, Sultan Alhayyani, Louise McLeod, Liang Yu, Mohammad Alanazi, Virginie Deswaerte, Ke Tang, Thierry Jarde, Julian A Smith, Zdenka Prodanovic, Michelle D Tate, Jesse J Balic, D Neil Watkins, Jason E Cain, Steven Bozinovski, Elizabeth Algar, Tomohiro Kohmoto, Hiromichi Ebi, Walter Ferlin, Christoph Garbers, Saleela Ruwanpura, Irit Sagi, Stefan Rose‐John, Brendan J Jenkins
Format: Article
Language:English
Published: Wiley 2019-04-01
Series:EMBO Molecular Medicine
Subjects:
ADAM17
ERK MAPK
IL‐6 trans‐signaling
KRAS
lung adenocarcinoma
Online Access:https://doi.org/10.15252/emmm.201809976

Internet

https://doi.org/10.15252/emmm.201809976

Similar Items